The global cancer burden and human development: A review
- PMID: 28669281
- DOI: 10.1177/1403494817715400
The global cancer burden and human development: A review
Abstract
Aims: This review examines the links between human development and cancer overall and for specific types of cancer, as well as cancer-related risk-factors and outcomes, such as disability and life expectancy.
Methods: To assess human development, the Human Development Index was utilized continuously and according to four levels (low, medium, high, very high), where the low and very high categories include the least and most developed countries, respectively. All studies that assessed aspects of the global cancer burden using this measure were reviewed.
Results: Although the present cancer incidence burden is greater in higher Human Development Index countries, a greater proportion of the global mortality burden is observed in less developed countries, with a higher mean fatality rate in the latter countries. Further, the future cancer burden is expected to disproportionally affect less developed regions; in particular, it has been estimated that low and medium Human Development Index countries will experience a 100% and 81% increase in cancer incidence from 2008 to 2030, respectively. Disparities were also observed in risk factors and average health outcomes, such as a greater number of years of life lost prematurely and fewer cancer-related gains in life expectancy observed in lower versus higher Human Development Index settings.
Conclusions: From a global perspective, there remain clear disparities in the cancer burden according to national Human Development Index scores. International efforts are needed to aid countries in social and economic transition in order to efficiently plan, implement and evaluate cancer control initiatives as a means to reduce the widening gap in cancer occurrence and survival worldwide.
Keywords: Cancer; global; human development; incidence; inequalities; review; socioeconomic.
Similar articles
-
Profiling global cancer incidence and mortality by socioeconomic development.Int J Cancer. 2020 Dec 1;147(11):3029-3036. doi: 10.1002/ijc.33114. Epub 2020 Jun 17. Int J Cancer. 2020. PMID: 32449164
-
Global patterns and trends in the breast cancer incidence and mortality according to sociodemographic indices: an observational study based on the global burden of diseases.BMJ Open. 2019 Oct 7;9(10):e028461. doi: 10.1136/bmjopen-2018-028461. BMJ Open. 2019. PMID: 31594871 Free PMC article.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
A global view on cancer incidence and national levels of the human development index.Int J Cancer. 2016 Dec 1;139(11):2436-46. doi: 10.1002/ijc.30382. Epub 2016 Aug 30. Int J Cancer. 2016. PMID: 27522007
-
Global Epidemiology of End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy.Am J Nephrol. 2021;52(2):98-107. doi: 10.1159/000514550. Epub 2021 Mar 22. Am J Nephrol. 2021. PMID: 33752206 Free PMC article. Review.
Cited by
-
Prognostic value of log odds of positive lymph nodes in node-positive lung squamous cell carcinoma patients after surgery: a SEER population-based study.Transl Lung Cancer Res. 2020 Aug;9(4):1285-1301. doi: 10.21037/tlcr-20-193. Transl Lung Cancer Res. 2020. PMID: 32953505 Free PMC article.
-
Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study.J Hematol Oncol. 2019 Sep 12;12(1):96. doi: 10.1186/s13045-019-0783-9. J Hematol Oncol. 2019. PMID: 31511035 Free PMC article.
-
The role of DNA mismatch repair in immunotherapy of human cancer.Int J Biol Sci. 2022 Apr 4;18(7):2821-2832. doi: 10.7150/ijbs.71714. eCollection 2022. Int J Biol Sci. 2022. PMID: 35541922 Free PMC article. Review.
-
Reg3A (regenerating family member 3 alpha) acts as a tumor suppressor by targeting DMBT1 (deleted in malignant brain tumors 1) in gastric cancer.Bioengineered. 2021 Dec;12(1):7644-7655. doi: 10.1080/21655979.2021.1981800. Bioengineered. 2021. PMID: 34605357 Free PMC article.
-
Visualized Analysis of Heavy Ion Radiotherapy: Development, Barriers and Future Directions.Front Oncol. 2021 Jul 9;11:634913. doi: 10.3389/fonc.2021.634913. eCollection 2021. Front Oncol. 2021. PMID: 34307120 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous